Phase III adjuvant studies in operable malignant melanoma (review)

Area of Science:

• Oncology
• Surgical Oncology
• Clinical Trials

Background:

• Adjuvant treatments are crucial for improving outcomes in primary melanoma patients post-surgery.
• Evaluating the efficacy of various adjuvant therapies in early-stage melanoma is essential.

Purpose of the Study:

• To review randomized trials assessing adjuvant treatments for stage I and II primary melanoma.
• To identify effective and ineffective treatment strategies to guide future research.

Main Methods:

• Systematic review of 21 randomized trials (1978-1986) for stage I melanoma (2,850 patients).
• Review of 15 studies for stage II melanoma (1,972 patients).
• Analysis of systemic chemotherapy, immunotherapy, chemo-immunotherapy, and regional perfusion protocols.

Main Results:

• No systemic chemotherapy, immunotherapy, or chemo-immunotherapy improved outcomes in stage I or II melanoma.
• Prophylactic isolation perfusion of the limbs with cytostatics showed promise in stage I melanoma.
• Current international trials are investigating this perfusion approach.

Conclusions:

• Systemic adjuvant therapies have largely failed to improve outcomes for stage I and II melanoma.
• Regional limb perfusion with cytostatics warrants further investigation as a potential adjuvant therapy for stage I melanoma.
• Understanding the reasons for systemic treatment failures is critical for developing novel therapeutic strategies.